Management of a Parkinson’s disease patient with severe COVID-19 pneumonia
Author(s) -
Jingwen Li,
Xi Long,
Chunli Zhu,
Ruiying Wang,
Shaoping Hu,
Tao Wang,
Jinghong Li,
Zhicheng Lin,
Nian Xiong
Publication year - 2020
Publication title -
therapeutic advances in chronic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.027
H-Index - 35
eISSN - 2040-6231
pISSN - 2040-6223
DOI - 10.1177/2040622320949423
Subject(s) - medicine , pneumonia , disease , coronavirus , covid-19 , parkinson's disease , intensive care medicine , encephalopathy , urinary system , pediatrics , infectious disease (medical specialty)
Elderly populations with underlying chronic diseases are more vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and have higher mortality. Parkinson’s disease (PD) is a neurodegenerative disease that occurs more often in elderly people. Currently, little is known about whether patients with PD are more susceptible to novel coronavirus disease 2019 (COVID-19) and whether the treatment of PD would affect the management of COVID-19 or vice versa. Here, we report a case of a PD patient with severe COVID-19 pneumonia in Wuhan, China. After diagnosis of COVID-19, this PD patient had worsening of motor symptoms, complicated with acute hypoxemic respiratory failure, urinary tract infection, and acute encephalopathy. In addition to treatment for COVID-19 and urinary tract infection, we adjusted anti-PD medicine by stepwise increasing of dose, resulting in better control of her mobility symptoms and non-motor symptoms.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom